While different authors demonstrate that obesity, as well as distinct treatment regimens including immune checkpoint blockage (anti-PD-1)56, gemcitabine57, and ranitidine58 affects the frequency of myeloid CD11b + populations in the TME and spleen of E0771 tumor-bearing mice, timepoints were limited, preventing observing the potential alterations throughout tumor development. The gene discussed is PDCD1; the disease is obesity due to melanocortin 4 receptor deficiency.